Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) reported positive mid-stage test results for its breast cancer drug ridaforolimus sending the stock price soaring 46 cents to $2.91.
Postive Trial Results For Ariad
July 28, 2009 at 13:53 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.